In the current study, negative impact of BCL-2 expression on CR was demonstrated in the TP53-negative carcinomas only, confirming our hypothesis that TP53-positive and TP53-negative ovarian carcinomas differ in clinical significance of apoptosis proteins interacting with TP53 in tumour response to cisplatin-based chemotherapy. Here, BCL2 is linked to carcinoma.